These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 22160654

  • 1. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
    Iwano S, Kato K, Ito S, Tsuchiya K, Naganawa S.
    Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S, Aksoy SY, Vatankulu B, Aliyev A, Uslu L, Ozhan M, Sager S, Halac M, Sonmezoglu K.
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [Abstract] [Full Text] [Related]

  • 9. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [Abstract] [Full Text] [Related]

  • 12. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [Abstract] [Full Text] [Related]

  • 13. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW, Lee SM, Lee DH, Kim YJ.
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [Abstract] [Full Text] [Related]

  • 14. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW, Furtado Mde S, Mineiro Filho AF, Lacerda RX, Calsolari MR.
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [Abstract] [Full Text] [Related]

  • 15. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
    Rizzo A, Perotti G, Zagaria L, Lanni V, Racca M, Palestini N, Salvatori M.
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
    [Abstract] [Full Text] [Related]

  • 16. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC.
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [Abstract] [Full Text] [Related]

  • 17. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 18. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M, Ung YC, Ehrlich L, Silverberg J, Balogh J, Wong CS.
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [Abstract] [Full Text] [Related]

  • 19. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY.
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [Abstract] [Full Text] [Related]

  • 20. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
    Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I.
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.